Benitec Biopharma Inc. (BNTC)
2025-03-31 | 2024-12-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Research and development | 5,980 | 5,072 | 3,585 | |
| General and administrative | 4,208 | 3,538 | 2,206 | |
| Total operating expenses | 10,188 | 8,610 | 5,791 | |
| Loss from operations | -10,188 | -8,610 | -5,791 | |
| Other expense, net | - | -40 | 35 | |
| Gain on extinguishment of liabilities | - | 764 | - | |
| Interest income (expense), net | 823 | 823 | 604 | |
| Foreign currency transaction gain (loss) | 11 | -294 | 93 | |
| Total other income (loss), net | 834 | 1,253 | 732 | |
| Net loss | -9,354 | -7,357 | -5,059 | |
| Basic eps | -0.24 | -0.33 | -0.48 | |
| Diluted eps | -0.24 | -0.33 | -0.48 | |
| Basic average shares | 38,599,453 | 22,075,332 | 10,644,533 | |
| Diluted average shares | 38,599,453 | 22,075,332 | 10,644,533 | |